Drug Approval | June 14, 2022
FDA accepts application for Merck’s Keytruda as adjuvant therapy for Stage IB-IIIA lung cancer
Acceptance based on results from the phase 3 KEYNOTE-091 trial
Acceptance based on results from the phase 3 KEYNOTE-091 trial
Next-generation booster vaccine candidate demonstrates potential to protect against COVID-19 variants of concern, including Omicron BA.1 and BA.2, with a favorable safety and tolerability profile
Amarex Clinical Research guides its client to phase II of FDA trials
The new subsidiary follows the recent announcement of Tetra's partnership with Cannvalate Pty Ltd for the performance of clinical trials of Tetra's drug candidates in Australia.
Immune-mediated events and infusion reactions were higher with KEYTRUDA (38% vs 9%, respectively).
C2i Genomics expands its global reach and brings the first whole-genome sequencing minimal residual disease test to India
Innate to receive $5M milestone payment from AstraZeneca
GSK to pay $2.1 billion upfront and up to $1.2 billion in potential development milestones
The new Oncology CRO will aim to drive faster execution and higher quality trial outcomes for Oncology sponsors.
Besides enhancing workflow operations by connecting scientists with their lab instruments and data, digitalization holds the potential to acceleratee long-term business growth
Subscribe To Our Newsletter & Stay Updated
